藥明康德(603259.SH):3名股東減持期屆滿 合計減持2.98%股份
格隆匯3月16日丨藥明康德(603259.SH)公佈,公司於2019年11月23日披露,Glorious Moonlight Limited、嘉世康恆(天津)投資合夥企業(有限合夥)和WuXi App Tec (BVI) Inc.(以下合稱“減持股東”)擬於2019年12月16日至2020年3月14日期間通過集中競價方式分別各減持公司股份不超過公司總股本的1%。
公司於2020年3月13日(為本次減持計劃減持時間區間屆滿日前最後一個交易日)收到減持股東分別發送的《上市公司股東股份減持計劃實施結果的告知函》。截至本次減持計劃時間區間屆滿日,減持股東就其於《股東減持計劃公告》中所披露的減持方式合計減持4914.4129萬股公司股份,佔公司目前總股本的2.98%,減持股東各自減持數量均未超過《股東減持計劃公告》所披露的計劃減持數量上限。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.